Teva Pharmaceutical Industries Limited (TEVA) Hits New 1-Year Low at $15.10

Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) reached a new 52-week low on Thursday . The stock traded as low as $15.10 and last traded at $15.07, with a volume of 14,974,204 shares changing hands. The stock had previously closed at $15.76.

Several analysts have recently weighed in on TEVA shares. Vetr raised Teva Pharmaceutical Industries Limited from a “sell” rating to a “hold” rating and set a $32.27 target price for the company in a report on Wednesday, June 28th. Royal Bank Of Canada reissued an “outperform” rating and issued a $37.00 target price (down from $38.00) on shares of Teva Pharmaceutical Industries Limited in a report on Monday, July 17th. Zacks Investment Research raised Teva Pharmaceutical Industries Limited from a “strong sell” rating to a “hold” rating in a report on Wednesday, October 4th. Goldman Sachs Group, Inc. (The) reissued a “neutral” rating and issued a $21.00 target price (down from $28.00) on shares of Teva Pharmaceutical Industries Limited in a report on Thursday, August 31st. Finally, BTIG Research raised Teva Pharmaceutical Industries Limited from a “neutral” rating to a “buy” rating and set a $24.00 target price for the company in a report on Monday, September 11th. Five research analysts have rated the stock with a sell rating, eighteen have given a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Teva Pharmaceutical Industries Limited presently has an average rating of “Hold” and a consensus price target of $27.63.

The firm has a 50 day moving average price of $16.80 and a 200-day moving average price of $26.36. The stock’s market cap is $15.37 billion.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last announced its earnings results on Thursday, August 3rd. The company reported $0.99 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $1.06 by ($0.07). Teva Pharmaceutical Industries Limited had a positive return on equity of 15.96% and a negative net margin of 25.18%. The firm had revenue of $5.69 billion for the quarter, compared to the consensus estimate of $5.72 billion. During the same period in the previous year, the firm earned $1.25 EPS. Teva Pharmaceutical Industries Limited’s revenue for the quarter was up 12.9% on a year-over-year basis. On average, equities analysts expect that Teva Pharmaceutical Industries Limited will post $4.25 earnings per share for the current year.

The company also recently announced a quarterly dividend, which was paid on Thursday, September 14th. Investors of record on Tuesday, August 29th were issued a dividend of $0.085 per share. The ex-dividend date was Friday, August 25th. This represents a $0.34 annualized dividend and a yield of 2.16%. Teva Pharmaceutical Industries Limited’s payout ratio is -15.36%.

A number of large investors have recently made changes to their positions in the stock. Capital Research Global Investors raised its holdings in Teva Pharmaceutical Industries Limited by 13.8% during the second quarter. Capital Research Global Investors now owns 76,325,059 shares of the company’s stock worth $2,535,518,000 after purchasing an additional 9,260,426 shares in the last quarter. Franklin Resources Inc. raised its holdings in Teva Pharmaceutical Industries Limited by 11.1% during the second quarter. Franklin Resources Inc. now owns 66,796,897 shares of the company’s stock worth $2,218,958,000 after purchasing an additional 6,685,844 shares in the last quarter. FMR LLC raised its holdings in Teva Pharmaceutical Industries Limited by 16.7% during the second quarter. FMR LLC now owns 42,844,979 shares of the company’s stock worth $1,423,310,000 after purchasing an additional 6,115,853 shares in the last quarter. Northern Cross LLC raised its holdings in Teva Pharmaceutical Industries Limited by 14.0% during the second quarter. Northern Cross LLC now owns 17,795,579 shares of the company’s stock worth $591,169,000 after purchasing an additional 2,184,172 shares in the last quarter. Finally, Nordea Investment Management AB raised its holdings in Teva Pharmaceutical Industries Limited by 2.5% during the second quarter. Nordea Investment Management AB now owns 12,884,810 shares of the company’s stock worth $428,033,000 after purchasing an additional 311,894 shares in the last quarter. 56.75% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: This article was first posted by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this article on another publication, it was copied illegally and reposted in violation of US and international copyright laws. The original version of this article can be read at https://sportsperspectives.com/2017/10/12/teva-pharmaceutical-industries-limited-teva-hits-new-1-year-low-at-15-10.html.

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply